

HETEROCYCLES, Vol. 72, 2007, pp. 681 - 689. © The Japan Institute of Heterocyclic Chemistry  
Received, 4th December, 2006, Accepted, 1st February, 2007, Published online, 6th February, 2007. COM-06-S(K)38

## SYNTHESIS OF ENANTIOMERICALLY ENRICHED 2-SUBSTITUTED PYRROLIDINE ANALOGUES OF NORHYGRINE. APPLICATION OF THE HETERO-DIELS-ALDER ADDITION OF SULFUR DIOXIDE


Māris Turks<sup>‡</sup> and Pierre Vogel<sup>\*</sup>

Laboratory of glycochemistry and asymmetric synthesis (LGSA), ISIC, Swiss Federal Institute of Technology (EPFL), CH-1015 Lausanne, Switzerland, Fax +41 21 693 93 75; e-mail: pierre.vogel@epfl.ch; <sup>‡</sup> Present address: Department of Chemistry Stanford University, CA 94305, USA


Dedicated to Professor Yoshito Kishi on the occasion of his 70<sup>th</sup> birthday

**Abstract** – The Vogel's reaction cascade (one-pot hetero-Diels-Alder addition of SO<sub>2</sub>, ionization of the sultines into zwitterions and their quenching by electron-rich alkenes) has been applied to the preparation of enantiomerically-enriched (1*S*)-2((2*R*)-1-benzoylpyrrolidin-2-yl)pentan-3-one (**14**). Reaction of SO<sub>2</sub> with (-)-(1*E*,3*Z*)-2-methyl-1-((1*S*)-1-phenylethoxy)penta-1,3-dien-3-ol benzoate (**5**; derived from (*S*)-1-phenylethanol (97% ee)) and allyltrimethylsilane in the presence of a Lewis acid at -78°C provides (-)-(2*Z*,1'*S*,4*S*,5*S*)-4-methyl-5-(1'-phenylethoxy)octa-2,7-dien-3-ol benzoate (**9**). Selective cleavage of the benzyl ether of **9** and subsequent S<sub>N</sub>2 displacement with Ph<sub>2</sub>P(O)N<sub>3</sub> provided an azide **11** that was converted into **14**.

Pyrrolidines are found in Nature<sup>1</sup> and as pharmacophores in drugs.<sup>2</sup> The active ingredients of toxic herbs are often pyrrolidine derivatives.<sup>3</sup> Simple derivatives such as hygrine (**1**) and norhygrine (**2**) are present in several plants.<sup>4</sup> Recently, enantiomerically pure "*trans*-lactams" of type **3** have been shown to be potent human cytomegalovirus (HCMV) protease inhibitors.<sup>5</sup> HCMV is one of the nine known human herpes viruses.<sup>6</sup>




Although several reports<sup>7</sup> present synthesis of pyrrolidine derivatives, relatively few are the methods for the enantioselective preparation of 2-substituted pyrrolidines analogues of **1** – **2**.<sup>8</sup> A close analogue of the system described here would be compound **4** (derived from (*R*)- $\alpha$ -methyl benzylamine).<sup>8b</sup> We disclosed here our synthesis of (1*S*)-2-((2*R*)-1-benzoylpyrrolidin-2-yl)pentan-3-one (**14**), a new compound derived from enantiomerically enriched (97%) (-)-(1*E*,3*Z*)-2-methyl-1-((1*S*)-1-phenylethoxy)penta-1,3-dien-3-ol benzoate (**5**), a diene obtained in three steps from inexpensive (1*S*)-1-phenylethanol (97% ee).<sup>9</sup> The method uses new organic chemistry of sulfur dioxide developed in our laboratory.<sup>10</sup>



In the presence of an excess of sulfur dioxide in  $\text{CH}_2\text{Cl}_2$  and a catalytic amount of  $(\text{CF}_3\text{SO}_2)_2\text{NSiMe}_3$  (Lewis acid promoter) diene (**5**) equilibrates with the corresponding sulfone **6**. At  $-78^\circ\text{C}$  the latter is ionized into zwitterions **7** that is quenched by allyltrimethylsilane giving sulfinate **8**. After  $\text{SO}_2$  evaporation at  $-78^\circ\text{C}$ , treatment of the crude reaction mixture with  $\text{Et}_3\text{NH}^+\text{CF}_3\text{SO}_3^-$  (made *in situ* from  $\text{Et}_3\text{N}$ ,  $\text{CF}_3\text{SO}_3\text{SiMe}_3$  and  $\text{MeOH}$ ) buffer in anhydrous methanol ( $-78$  to  $-50^\circ\text{C}$ ) led to desulfinylation producing **9**.<sup>11</sup> Cleavage of the (1*S*)-phenylethyl ether moiety of **9** was induced by  $\text{CF}_3\text{COOH}$  (10 equiv.) in  $\text{CH}_2\text{Cl}_2$  containing one equivalent of anisole. This gave **10** in 75% yield, together with 15% of

(3*S*,4*S*)-4-methyl-5-oxooct-1-en-3-ol benzoate (product of benzoyl group migration). The enantiomeric excess of alcohol **10** was the same as that of the (1*S*)-phenylethanol used to prepare diene **5** (97% ee), as proven by <sup>19</sup>F-NMR (CDCl<sub>3</sub>) of the (*S*)-MTPA and (*R*)-MTPA Mosher's ester **10S** and **10R**. The (3*S*)-absolute configuration of **10** was suggested by the <sup>1</sup>H-chemical shifts of H<sub>2</sub>C(2) and H-C(4) of **10S** and **10R**<sup>12</sup> and confirmed by X-ray radiocrystallography of a derivative of the enantiomer of **10**.<sup>11</sup>



Reaction of alcohol **10** with Ph<sub>2</sub>P(O)N<sub>3</sub> in the presence of diethyl azodicarboxylate and triphenylphosphine<sup>13</sup> provided azide **11** in 82% yield. Hydroboration followed by oxidation of alkene **11** (BH<sub>3</sub>·THF, work-up with 30% aq. H<sub>2</sub>O<sub>2</sub>)<sup>14</sup> gave alcohol **12** (40%) and unreacted **11** (22%). Dess-Martin oxidation of **12** furnished aldehyde **13** (80%). Reduction of azide **13** with H<sub>2</sub>/10% Pd/C in MeOH led to **14**, resulting from the conversion of the azide into a primary amine that cyclized with the aldehyde forming an intermediate imine that was hydrogenated into a pyrrolidine. Migration of the benzoyl group from the enol ester to the nitrogen atom of pyrrolidine finally produced **14**.

This note demonstrates that the new organic chemistry of sulfur dioxide developed to generate polyketide and polypropionate fragments<sup>11</sup> can be used to prepare enantiomerically enriched pyrrolidine analogue of hygrine and norhygrine.

## EXPERIMENTAL

*General*, see ref. 9. <sup>1</sup>H-NMR assignments were confirmed by 2D-(COSY, NOESY)-<sup>1</sup>H-NMR spectra.

(-)-(6*Z*,1'*S*,4*S*,5*S*)-5-Methyl-5-(1'-phenylethoxy)octa-1,6-dien-6-yl benzoate (**9**). Allyltrimethylsilane (0.2 mL, 1.26 mmol) and 0.5 M (CF<sub>3</sub>SO<sub>2</sub>)NH in CH<sub>2</sub>Cl<sub>2</sub> (0.25 mL, 1.26 mmol) were mixed in CH<sub>2</sub>Cl<sub>2</sub> (7 mL) and stirred at 20°C for 10 min. Then SO<sub>2</sub> (ca. 7 mL) dried over a column of P<sub>2</sub>O<sub>5</sub> and Al<sub>2</sub>O<sub>3</sub> was transferred through the vacuum line to the frozen solution (-196°C). The mixture was allowed to melt and to warm to -78°C. After 30 min at this temperature a mixture of (-)-(1*E*,3*Z*)-2-methyl-1-((1*S*)-1-phenylethoxy)penta-1,3-dien-3-ol benzoate (**5**) [9] (1.45 g, 4.2 mmol) and allyltrimethylsilane (1.34 mL, 8.4 mmol) in anh. CH<sub>2</sub>Cl<sub>2</sub> (0.7 mL) was added dropwise under vigorous stirring at -78°C. The mixture was stirred at -78°C for 24 h. Sulfur dioxide and CH<sub>2</sub>Cl<sub>2</sub> were evaporated at -78°C under vacuum for 2 h. Then a premixed solution of Et<sub>3</sub>N (0.76 mL, 5.45 mmol), CF<sub>3</sub>SO<sub>3</sub>SiMe<sub>3</sub> (0.76 mL, 4.2 mmol) in anh. MeOH (2 mL) was

added at  $-78^{\circ}\text{C}$  under vigorous stirring. The temperature was allowed to reach  $-50^{\circ}\text{C}$  over 3 h. The reaction mixture was poured into a ice-cold sat. aq. soln. of  $\text{NaHCO}_3$  (50 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  (30 mL, 3 times). The combined org. extracts were washed successively, with sat. aq. soln. of  $\text{NaHCO}_3$  (20 mL), brine (10 mL) and dried ( $\text{Na}_2\text{SO}_4$ ). After solvent evaporation *in vacuo* the residue was purified by flash chromatography on silica gel (light petroleum ether/EtOAc 96:4) giving 1.07 g (70%) colorless oil.  $[\alpha]_{\text{D}}^{25} = -34$ ,  $[\alpha]_{577}^{25} = -41$ ,  $[\alpha]_{546}^{25} = -36$ ,  $[\alpha]_{435}^{25} = -54$ ,  $[\alpha]_{405}^{25} = -63$  ( $c = 1.04$ ,  $\text{CHCl}_3$ ). IR (film)  $\nu$ : 3065, 2975, 2925, 1730, 1695, 1600, 1450, 1260, 1175, 1090  $\text{cm}^{-1}$ .  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ : 8.08 (*d*, 2H,  $^3J = 7.4$ , Bz), 7.65 (*t*, 1H,  $^3J = 7.7$ , Bz), 7.50 (*t*, 2H,  $^3J = 7.7$ , Bz), 7.23-7.20 (*m*, 2H, Ph), 7.17-7.14 (*m*, 3H, Ph), 5.69 (*dxdxt*, 1H,  $^3J = 17.3$ ,  $^3J = 10.2$ ,  $^3J = 7.0$ , H-C(2)), 5.33 (*q*, 1H,  $^3J = 7.0$ , H-C(7)), 5.06-4.96 (*m*, 2H, H-C(1)), 4.50 (*q*, 1H,  $^3J = 6.4$ , H-C(1')), 3.50 (*dxt*, 1H,  $^3J = 7.7$ ,  $^3J = 4.2$ , H-C(4)), 2.97 (*m*, 1H, H-C(5)), 2.28-2.15 (*m*, 2H, H-C(3)), 1.58 (*d*, 3H,  $^3J = 7.0$ , H-C(8)), 1.44 (*d*, 3H,  $^3J = 6.4$ , H-C(2')), 1.20 (*d*, 3H,  $^3J = 7.0$ , Me-C(5)).  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$ : 164.1 (*s*, CO), 150.2 (*s*, C(6)), 143.6 (*s*, Ar), 136.0 (*d*,  $^1J(\text{C,H}) = 153$ , Ar), 133.2 (*d*,  $^1J(\text{C,H}) = 160$ , Ar), 129.9 (*d*,  $^1J(\text{C,H}) = 165$ , Ar), 128.4 (*d*,  $^1J(\text{C,H}) = 163$ , Ar), 128.0 (*d*,  $^1J(\text{C,H}) = 162$ , Ar), 127 (*d*,  $^1J(\text{C,H}) = 160$ , Ar), 126.8 (*d*,  $^1J(\text{C,H}) = 160$ , Ar), 116.1 (*t*,  $^1J(\text{C,H}) = 145$ , C(1')), 75.7 (*d*,  $^1J(\text{C,H}) = 143$ , C(4)), 39.6 (*d*,  $^1J(\text{C,H}) = 128$ , C(5)), 34.8 (*t*,  $^1J(\text{C,H}) = 121$ , C(3)), 23.9 (*q*,  $^1J(\text{C,H}) = 129$ , C(2')), 11.6 (*q*,  $^1J(\text{C,H}) = 128$ , 4 Me), 11.0 (*q*,  $^1J(\text{C,H}) = 128$ , C(8)). MS-MALDI: Calcd for  $\text{C}_{24}\text{H}_{28}\text{O}_3\text{Na}^+$  387.1936 ( $M+\text{Na}^+$ ); found: 387.1935. Anal. Calcd for  $\text{C}_{24}\text{H}_{28}\text{O}_3$  (364.48): C 79.9, H 7.74. Found: C 79.12, H 7.72.

(+)-(6Z,4S,5S)-4-Hydroxy-5-methylocta-1,6-dien-6-yl benzoate (**10**). To a solution of (-)-**9** (3.9 g, 10.7 mmol) and anisole (1.22 mL, 10.7 mmol) in  $\text{CH}_2\text{Cl}_2$  (65 mL) at  $0^{\circ}\text{C}$  was added  $\text{CF}_3\text{COOH}$  (8.1 mL, 0.11 mol). The resulting brownish-pink solution was let to reach  $+15^{\circ}\text{C}$  in 2.5 h. Then it was neutralized with solid  $\text{NaHCO}_3$ , filtered and evaporated *in vacuo*. The residue was purified by flash chromatography (light petroleum ether/EtOAc 95:5): 2.09 g (75%) of **10**, and 0.42 g (15%) of (3S,4S)-4-methyl-5-oxooct-1-en-3-ol benzoate. Data of **10**. colorless oil.  $R_f = 0.29$  (petroleum ether/EtOAc = 9:1).  $[\alpha]_{\text{D}}^{25} = +24$ ,  $[\alpha]_{577}^{25} = +26$ ,  $[\alpha]_{435}^{25} = +39$ ,  $[\alpha]_{405}^{25} = +39$  ( $c = 0.41$ ,  $\text{CHCl}_3$ ). IR (film)  $\nu$ : 3515, 3070, 2975, 2920, 1735, 1715, 1690, 1600, 1450, 1285, 1260, 1175, 1095, 1070  $\text{cm}^{-1}$ .  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ : 8.14 (*d*,  $^3J = 8.4$ ,  $^4J = 1.3$ , H-C(Bz)), 7.64 (*txt*,  $^3J = 7.0$ ,  $^4J = 1.3$ , H-C(Bz)), 7.51 (*t*, 2H,  $^3J = 8.3$ , H-C(Bz)), 5.94 (*dxdxdxd*, 1H,  $^3J = 16.6$ ,  $^3J = 10.2$ ,  $^3J = 7.7$ ,  $^3J = 6.4$ , H-C(2)), 5.39 (*q*, 1H,  $^3J = 7.0$ , H-C(7)), 5.12 (*dxq*, 1H,  $^3J = 16.6$ ,  $^2J = 1.3$ ,  $^4J = 1.3$ , Ha-C(1)), 5.09 (*dxdxd*, 1H,  $^3J = 10.2$ ,  $^2J = 1.2$ ,  $^4J = 1.2$ , Hb-C(1)), 3.43 (*dxtxd*, 1H,  $^3J = 8.3$ ,  $^3J = 3.8$ ,  $^3J = 2.6$ , H-C(4)), 3.26 (*d*, 1H,  $^3J = 2.6$ , HO-C(4)), 2.44 (*dxq + m*, 2H,  $^3J = 8.9$ ,  $^3J = 7.0$ , H-C(5)), Ha-C(3)), 2.16 (*dxt*, 1H,  $^2J = 14.5$ ,  $^3J = 7.7$ , Hb-C(3)), 1.53 (*d*, 3H,  $^3J = 7.0$ , H-C(2')), 1.12 (*d*, 3H,  $^3J = 7.0$ ,  $\text{CH}_3$ -C(5)).  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$ : 165.5, 149.4, 135.1, 133.8, 130.2, 128.8, 128.7, 117.1,

114.6, 71.4, 45.8, 38.0, 14.5, 11.1. MS-MALDI: Calcd for  $C_{16}H_{20}O_3Na^+$  283.1310; found: 283.1389. Anal. Calcd for  $C_{16}H_{20}O_3$  (260.33): C 73.82, H 7.74. Found: C 73.76, H 7.80.

(6*Z*,4*S*,5*S*)-5-Methyl-4-(((2*R*)-3,3,3-trifluoro-2-methoxy-2-phenylpropionyl)oxy)octa-1,6-dien-6-yl benzoate (**10R**). To a solution of (+)-**10** (26 mg, 0.10 mmol) in pyridine (0.5 mL) at  $-15^\circ\text{C}$  was added (*S*)-1-methoxy-1-trifluoromethyl-1-phenylacetyl chloride (50 mg, 0.20 mmol). The resulting mixture was allowed to reach  $20^\circ\text{C}$  and stirred for 2 h. It was then chilled to  $-20^\circ\text{C}$  and *N,N*-dimethylaminoethanol (20 mg, 0.20 mmol) was added. The mixture was allowed to warm to  $-20^\circ\text{C}$  and stirred for 1 h. It was diluted with  $\text{Et}_2\text{O}$  (30 mL), washed successively with a sat. aq. soln. of  $\text{CuSO}_4$  (7 mL, 4 times), water (10 mL) 10% aq. soln. of citric acid (7 mL, 4 times), sat. aq. soln. of  $\text{NaHCO}_3$  (5 mL, 3 times), dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated *in vacuo*. Yield: 44 mg (93%) of **10R**. All the NMR measurements were done on the crude sample. Data of **10R**: colorless oil.  $R_f = 0.44$  (petroleum ether/ $\text{EtOAc}$  9:1).  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ : 8.09 (*dd*, 2H,  $^3J = 8.0$ ,  $^4J = 1.3$ , H-C(Bz)), 7.64 (*tt*, 1H,  $^3J = 7.0$ ,  $^4J = 1.3$ , H-C(Bz)), 7.58-7.32 (*m*, 7H, H-C(Ar)), 5.78 (*dxdxdxd*, 1H,  $^3J = 17.3$ ,  $^3J = 10.0$ ,  $^3J = 8.0$ ,  $^3J = 6.2$ , H-C(2)), 5.30 (*dxdxd*, 1H,  $^3J = 8.0$ ,  $^3J = 6.8$ ,  $^3J = 4.3$ , H-C(4)), 5.24 (*q*, 1H,  $^3J = 6.8$ , H-C(7)), 5.12 (*dm*, 1H,  $^3J = 17.3$ , Ha-C(1)), 5.12 (*dm*, 1H,  $^3J = 10.0$ , Hb-C(1)), 3.54 (*br. q*, 3H,  $^5J_{\text{H,F}} = 1.2$ ,  $\text{CH}_3\text{O-C}(2'')$ ), 2.76 (*quint*, 1H,  $^3J = 6.8$ , H-C(5)), 2.60 (*dxdxdxd*, 1H,  $^2J = 14.8$ ,  $^3J = 5.7$ ,  $^3J = 3.8$ ,  $^4J = 1.9$ , Ha-C(3)), 2.42 (*dt*, 1H,  $^2J = 14.8$ ,  $^3J = 8.0$ , Hb-C(3)), 1.44 (*d*, 3H,  $^3J = 7.4$ , H-C(8)), 1.01 (*d*, 3H,  $^3J = 7.0$ ,  $\text{CH}_3\text{-C}(5)$ ).  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$ : 166.2, 164.0, 148.0, 133.4, 133.3, 132.4, 130.1, 129.5, 129.4, 128.6, 128.3, 127.5, 123.4 (*q*,  $^1J_{\text{C,F}} = 288$ ,  $\text{CF}_3$ ), 118.6, 133.8, 77.2, 55.6, 41.5, 35.1, 13.4, 11.2.  $^{19}\text{F-NMR}$  ( $\text{CDCl}_3$ , 376.7 MHz)  $\delta_{\text{F}}$ : -71.78 (*s*,  $\text{CF}_3$ ). MS-MALDI: Calcd for  $\text{C}_{26}\text{H}_{27}\text{F}_3\text{O}_5\text{Na}^+$  499.1708; found: 499.1712.

(6*Z*,4*S*,5*S*)-5-Methyl-4-(((2*S*)-3,3,3-trifluoro-2-methoxy-2-phenylpropionyl)oxy)octa-1,6-dien-6-yl benzoate (**10S**). Same procedure as that for **10R**, using (*R*)-1-methoxy-1-trifluoromethyl-1-phenylacetyl chloride. Yield: 94%. Colorless oil,  $R_f = 0.44$  (petroleum ether/ $\text{EtOAc}$  9:1).  $^1\text{H-NMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$ : 8.11 (*dd*, 2H,  $^3J = 7.4$ ,  $^4J = 1.2$ , H-C(Bz)), 7.64 (*tt*, 1H,  $^3J = 7.4$ ,  $^4J = 1.2$ , H-C(Bz)), 7.58-7.35 (*m*, 7H, H-C(Ar)), 5.78 (*dxdxdxd*, 1H,  $^3J = 15.4$ ,  $^3J = 10.0$ ,  $^3J = 8.6$ ,  $^3J = 6.2$ , H-C(2)), 5.34 (*m*, 2H, H-C(4), H-C(7)), 5.04 (*br. d*, 1H,  $^3J = 15.4$ , Ha-C(1)), 5.12 (*br. d*, 1H,  $^3J = 10.0$ , Hb-C(1)), 3.55 (*br. q*, 3H,  $^5J_{\text{H,F}} = 1.2$ ,  $\text{CH}_3\text{O-C}(2'')$ ), 2.79 (*quint*, 1H,  $^3J = 6.8$ , H-C(5)), 2.54 (*dxdxt*, 1H,  $^2J = 14.8$ ,  $^3J = 6.2$ ,  $^3J = 2.0$ ,  $^4J = 2.0$ , Ha-C(3)), 2.34 (*dt*, 1H,  $^2J = 14.8$ ,  $^3J = 7.4$ , Hb-C(3)), 1.50 (*d*, 3H,  $^3J = 6.8$ , H-C(8)), 1.15 (*d*, 3H,  $^3J = 6.8$ ,  $\text{CH}_3\text{-C}(5)$ ).  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$ : 166.2, 164.0, 148.3, 133.5, 132.6, 132.4, 130.2, 129.6, 129.2, 128.6, 128.4, 127.6, 123.5 (*q*,  $^1J_{\text{C,F}} = 288$ ,  $\text{CF}_3$ ), 118.7, 133.8, 77.1, 55.5, 41.5, 35.2, 14.0, 11.3.  $^{19}\text{F-NMR}$  ( $\text{CDCl}_3$ , 376.7 MHz)  $\delta_{\text{F}}$ : -71.65 (*s*,  $\text{CF}_3$ ). MS-MALDI: Calcd for  $\text{C}_{26}\text{H}_{27}\text{F}_3\text{O}_5\text{Na}^+$  499.1708; found: 499.1724.

(+)-(6Z,4R,5R)-4-Azido-5-methylocta-1,6-dien-6-yl benzoate (**11**). To a chilled (-30°C) solution of (+)-**10** (1.34 g, 5.13 mmol) and Ph<sub>3</sub>P (1.42 g, 5.28 mmol) in THF (45 mL) were sequentially added diethyl azodicarboxylate (DEAD, 0.84 mL, 5.38 mmol) and Ph<sub>2</sub>P(O)N<sub>3</sub> (1.17 mL, 5.38 mmol). The resulting mixture was allowed to reach +5°C in 2 h and stirred at this temperature for 2 more hours. Then it was poured into brine (50 mL) and the aqueous phase was extracted with Et<sub>2</sub>O (30 mL, 3 times). The combined organic layers were washed with brine (30 mL) dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated. The resulting oil was purified by flash chromatography on silica gel (light petroleum ether/EtOAc 95:5) yielding 1.2 g (82%), colorless oil, *R*<sub>f</sub> = 0.72 (light petroleum ether/EtOAc 9:1).  $[\alpha]_{\text{D}}^{25} = +1.0$ ,  $[\alpha]_{577}^{25} = +1.5$ ,  $[\alpha]_{546}^{25} = +2.3$ ,  $[\alpha]_{435}^{25} = +7.9$ ,  $[\alpha]_{405}^{25} = +11.0$  (*c* = 0.48, CHCl<sub>3</sub>). IR (film)  $\nu$ : 2980, 2920, 2100, 1735, 1695, 1450, 1260, 1090 cm<sup>-1</sup>. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 8.14 (*dxd*, 2H, <sup>3</sup>*J* = 7.4, H-C(Bz)), 7.64 (*t*, 1H, <sup>3</sup>*J* = 7.4, H-C(Bz)), 7.51 (*t*, 2H, <sup>3</sup>*J* = 7.4, H-C(Bz)), 5.83 (*dxdxt*, 1H, <sup>3</sup>*J* = 17.2, <sup>3</sup>*J* = 10.5, <sup>3</sup>*J* = 6.8, H-C(2)), 5.35 (*q*, <sup>3</sup>*J* = 6.8, H-C(7)), 5.19 (*dxq*, 1H, <sup>3</sup>*J* = 16.6, <sup>4</sup>*J* = 1.2, Ha-C(1)), 5.14 (*dxq*, 1H, <sup>3</sup>*J* = 9.8, <sup>4</sup>*J* = 1.9, Hb-C(1)), 3.53 (*dxt*, 1H, <sup>3</sup>*J* = 8.6, <sup>3</sup>*J* = 5.5, H-C(4)), 2.57 (*qxd*, 1H, <sup>3</sup>*J* = 6.8, <sup>3</sup>*J* = 5.5, H-C(5)), 2.45, 2.37 (*2m*, ABXY, <sup>2</sup>*J* = 14.8, <sup>3</sup>*J* = 8.6, <sup>3</sup>*J* = 6.8, H<sub>2</sub>C(3)), 1.56 (*d*, 3H, <sup>3</sup>*J* = 6.8, H-C(8)), 1.20 (*d*, 3H, <sup>3</sup>*J* = 6.8, CH<sub>3</sub>-C(5)). <sup>13</sup>C-NMR (100.6 MHz, CDCl<sub>3</sub>)  $\delta_{\text{C}}$ : 164.1, 149.5, 134.2, 133.5, 130.1, 129.4, 128.6, 118.3, 113.3, 64.4, 42.4, 37.0, 13.3, 11.1. MS-CI (NH<sub>3</sub>) *m/z*: 304 ([*M*+19]<sup>+</sup>, 100), 303 ([*M*+18]<sup>+</sup>, 71), 287 ([*M*+2]<sup>+</sup>, 77), 286 ([*M*+1]<sup>+</sup>, 244 (20), 243 (22), 190 (24), 189 (33), 137 (100) 136 (100), 106 (100), 105 (100). MS-MALDI: Calcd for C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>Na<sup>+</sup> 308.1375; found: 308.1343. Anal. Calcd for C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> (285.34): C 67.35, H 6.71, N 14.73. Found: C 67.39, H 6.64, N 14.69.

(6Z,4R,5S)-4-Azido-1-hydroxy-5-methyloct-6-en-6-yl benzoate (**12**). To a solution of (+)-**11** (0.125 g, 0.44 mmol) in THF (2 mL) was added 1 M solution of BH<sub>3</sub>·THF in THF (0.22 mL, 0.22 mmol) at 0°C. The resulting mixture was stirred at 0°C for 2 h. It was cooled to -78°C and quenched with MeOH (0.14 mL). Then water (0.7 mL), NaHCO<sub>3</sub> (0.24 g) and 30% aq. soln. of H<sub>2</sub>O<sub>2</sub> (0.4 mL) were added successively. The mixture was stirred at 5°C for 7 h. EtOAc (20 mL) was added, phases were separated, and organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and evaporated. The resulting oil was purified by flash column chromatography on silica gel (light petroleum ether/EtOAc 7:3) yielding 53 mg (40%) of **12** and unreacted (+)-**11** (28 mg, 22%). Data of **12**: colorless oil, *R*<sub>f</sub> = 0.37 (light petroleum ether/EtOAc 7:3), <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 8.12 (*dd*, 2H, <sup>3</sup>*J* = 8.4, H-C(Bz)), 7.62 (*t*, 1H, <sup>3</sup>*J* = 7.4, H-C(Bz)), 7.50 (*t*, 2H, <sup>3</sup>*J* = 7.8, H-C(Bz)), 5.34 (*q*, 1H, <sup>3</sup>*J* = 7.4, H-C(7)), 3.66 (*t*, 2H, <sup>3</sup>*J* = 5.8, H-C(1)), 3.44 (*dxdxd*, 1H, <sup>3</sup>*J* = 9.0, <sup>3</sup>*J* = 6.4, <sup>3</sup>*J* = 3.2, H-C(4)), 2.56 (*qxd*, 1H, <sup>3</sup>*J* = 7.0, <sup>3</sup>*J* = 6.4, H-C(5)), 1.88 (*br. s*, 1H, HO-C(1)), 1.84-1.72, 1.66-1.58 (*2m*, 4H, H-C(2), H-C(3)), 1.55 (*d*, 3H, <sup>3</sup>*J* = 7.0, H-C(8)), 1.20 (*d*, 3H, <sup>3</sup>*J* = 7.0,

CH<sub>3</sub>-C(5)). <sup>13</sup>C-NMR (100.6 MHz, CDCl<sub>3</sub>) δ<sub>C</sub>: 164.3, 149.5, 133.6, 130.1, 129.3, 128.7, 113.3, 64.9, 62.2, 43.1, 29.7, 29.0, 13.5, 11.1. MS-MALDI: Calcd for C<sub>16</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>K<sup>+</sup> 342.1220; found: 342.1255.

(6*Z*,4*R*,5*S*)-4-Azido-6-benzoyloxy-5-methyl-6-octenal (**13**). To a solution of alcohol **12** (38 mg, 0.127 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added Dess-Martin periodinane (0.135 g, 0.318 mmol) at 0°C. The resulting mixture was stirred at 25°C for 1 h. It was quenched by addition of sat. aq. soln. of NaHCO<sub>3</sub> (2 mL) followed by Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>·5 H<sub>2</sub>O (0.5 g). Extractive work-up (CH<sub>2</sub>Cl<sub>2</sub>, 3 mL, 3 times), drying (Na<sub>2</sub>SO<sub>4</sub>) and evaporation provided the crude product which was purified by flash column chromatography on silica gel (light petroleum ether/EtOAc 8:2) giving 29 mg (80%), colorless oil. *R*<sub>f</sub> = 0.74 (CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O 95:5). IR (film) ν: 2980, 2920, 2110, 1730, 1695, 1600, 1455, 1260, 1090 cm<sup>-1</sup>. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ<sub>H</sub>: 9.18 (*s*, 1H, H-C(1)), 8.13 (*dxd*, 2H, <sup>3</sup>*J* = 8.4, <sup>4</sup>*J* = 1.2, H-C(Bz)), 7.64 (*txt*, 1H, <sup>3</sup>*J* = 7.4, <sup>4</sup>*J* = 1.2, H-C(Bz)), 7.51, *t*, 2H, <sup>3</sup>*J* = 7.8, H-C(Bz)), 5.37 (*q*, 1H, <sup>3</sup>*J* = 6.8, H-C(7)), 3.44 (*dxdxd*, 1H, <sup>3</sup>*J* = 9.8, <sup>3</sup>*J* = 6.2, <sup>3</sup>*J* = 3.1, H-C(4)), 2.71-2.55 (*m*, 2H, H-C(2)), 2.05 (*dxdxdxd*, 1H, <sup>2</sup>*J* = 14.3, <sup>3</sup>*J* = 8.0, <sup>3</sup>*J* = 6.8, <sup>3</sup>*J* = 3.6, Ha-C(3)), 1.80 (*dxdxdxd*, 1H, <sup>2</sup>*J* = 14.3, <sup>3</sup>*J* = 9.8, <sup>3</sup>*J* = 8.0, <sup>3</sup>*J* = 5.5, Hb-C(3)), 1.55 (*d*, 3H, <sup>3</sup>*J* = 6.8, H-C(8)), 1.22 (*d*, 3H, <sup>3</sup>*J* = 6.8, CH<sub>3</sub>-C(5)). MS-MALDI: Calcd for C<sub>16</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>Na<sup>+</sup> 324.1324; found: 324.1387.

(1*S*)-2-((2*R*)-1-Benzoylpyrrolidin-2-yl)pentan-3-one (**14**). To a solution of **13** (25 mg, 0.084 mmol) in MeOH (1 mL) was added Pd/C (10% Pd on C) (5 mg) and the resulting suspension was stirred under H<sub>2</sub> atmosphere (1 bar) for 3 h. Filtration of catalyst and evaporation of solvent provided 17 mg (79%) of pure **14**, colorless oil. *R*<sub>f</sub> = 0.12 (CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>2</sub>O 95:5). <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) δ<sub>H</sub>: 7.50-7.37 (*m*, 5H, H-C(Bz)), 4.40 (*dt*, 1H, <sup>3</sup>*J* = 8.3, <sup>3</sup>*J* = 5.8, H-C(2')), 3.55 (*dq*, 1H, <sup>3</sup>*J* = 7.0, <sup>3</sup>*J* = 5.1, H-C(2)), 3.44 (*dd*, 2H, <sup>3</sup>*J* = 9.0, <sup>3</sup>*J* = 3.8, H-C(5')), 2.50 (*q*, 2H, <sup>3</sup>*J* = 7.0, H-C(4)), 2.17-2.01 (*m*, 2H, H-C(3')), 1.88-1.81, 1.70-1.58 (2*m*, 2H, H-C(4')), 1.17 (*d*, 3H, <sup>3</sup>*J* = 7.0, H-C(1)), 1.05 (*t*, 3H, <sup>3</sup>*J* = 7.0, H-C(5)). <sup>13</sup>C-NMR (100.6 MHz, CDCl<sub>3</sub>) δ<sub>C</sub>: 214.4, 170.4, 137.0, 130.3, 128.3, 127.4, 60.0, 51.3, 45.8, 36.5, 26.9, 25.2, 13.6, 7.8. MS-MALDI: Calcd for C<sub>16</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>Na<sup>+</sup> 282.1470; found: 282.1478.

## ACKNOWLEDGEMENTS

This work was supported by the *Swiss National Science Foundation* and the *Secrétariat d'Etat à l'éducation et à la recherche, SER, Bern* (FP6 European project TRIOH). We thank Mr. F. Sepulveda and Dr. S. R. Dubbaka for technical help.

## REFERENCES

1. V. A. Snieckus, *Alkaloids* (London), 1974, **4**, 50; 1975, **5**, 56; A. R. Pinder, *Alkaloids* (London), 1976, **6**, 54; J. D. Hunt and A. McKillop, *Rodd's Chem. Carbon Compd.* 2<sup>nd</sup> ed., 1977, **4B**, 1; G. Massiot and C. Delaude, *Alkaloids* (Academic Press), 1986, **27**, 269; A. R. Pinder, *Nat. Prod. Rep.*, 1987, **4**, 527; 1989, **6**, 67; 1990, **7**, 447; 1992, **9**, 17; A. O. Plunkett, *Nat. Prod. Rep.*, 1994, **11**, 581; D. J. Robins, *Rodd's Chem. Carbon Compd.* 2<sup>nd</sup> ed., 1997, **4B**, 1; K. Jenett-Siems, R. Weigl, A. Boehm, P. Mann, B. Tofern-Reblin, S. C. Ott, A. Ghomian, M. Kaloga, K. Siems, L. Witte, M. Hilker, F. Mueller, and E. Eich, *Phytochemistry*, 2005, **66**, 1448; D. Tsukamoto, M. Shibano, and G. Kusano, *Natural Medicines* (Tokyo, Japan), 2003, **57**, 68; H. Takayama, T. Ichikawa, T. Kuwajima, M. Kitajima, H. Seki, N. Aimi, and M. G. Nonato, *J. Am. Chem. Soc.*, 2000, **122**, 8635; M. Tsuda, M. Sasaki, T. Mugishima, K. Komatsu, T. Sone, M. Tanaka, Y. Mikami, and J. Kobayashi, *J. Nat. Prod.*, 2005, **68**, 273.
2. See e.g.: P. Chand, *Expert Opinion on Therapeutic Patents*, 2005, **15**, 1009; Q. Li and W. Xu, *Curr. Med. Chem. Anti-Cancer Agents*, 2005, **5**, 53; V. Pande and M. J. Ramos, *Curr. Med. Chem.*, 2003, **10**, 1603; G. Stamatiou, G. B. Foscolos, G. Fytas, A. Kolocouris, N. Kolocouris, C. Pannecouque, M. Witvrouw, E. Padalko, J. Neyts, and E. De Clerq, *Bioorg. Med. Chem.*, 2003, **11**, 5485; L. G. Neyens, W. C. Alpherts, and A. P. Aldenkamp, *Prog. Neuro-Psychopharm. Biol. Psychiatry*, 1995, **19**, 411; S. Ohki, T. Nagasaka, H. Matsuda, N. Ozawa, and F. Hamaguchi, *Chem. Pharm. Bull.*, 1986, **34**, 3606; N. Uchide and K. Ohyama, *J. Antimicrob. Chemother.*, 2003, **52**, 8.
3. R. J. Huxtable, *General Pharmacology*, 1979, **10**, 159; A. E. Johnson, R. J. Molyneux, and G. B. Merrill, *J. Agric. Food Chem.*, 1985, **33**, 50.
4. See e.g.: A. J. Parr, J. Payne, J. Eagles, B. T. Chapman, R. J. Robins, and M. J. C. Rhodes, *Phytochemistry*, 1990, **29**, 2545; J. F. Stevens, H. Hart, H. Hendriks, and T. M. Malingré, *Phytochemistry*, 1992, **31**, 3917; J. H. K. Kim, H. Hart, and J. F. Stevens, *Phytochemistry*, 1996, **41**, 1319; A. B. Pomilio, M. D. Gonzáles, and C. C. Eceizabarrena, *Phytochemistry*, 1996, **41**, 1393.
5. W. M. Seganish and B. B. Jarvis, *Chemtracts*, 2002, **15**, 367; A. D. Borthwick, *Med. Res. Rev.*, 2005, **25**, 427.
6. D. M. Knipe and P. M. Howley, *Fields Virology*, Lippincott Williams & Wikins, Philadelphia, 2001, Vol. 2; R. J. Cohrs and D. H. Gilden, *Brain Patol.*, 2001, **11**, 465.
7. W. H. Pearson, *Studies in Natural Products Chemistry*, 1988, **1**, 323; A. Job, C. F. Janeck, W. Bettray, R. Peters, and D. Enders, *Tetrahedron*, 2002, **58**, 2253; F.-X. Felpin and J. Lebreton, *Eur. J. Org. Chem.*, 2003, 2693; P. Zhou, B.-C. Chen, and F. A. Davis, *Tetrahedron*, 2004, **60**, 8003; S. G. Pyne, A. S. Davis, N. J. Gates, J. P. Hartley, K. B. Lindsay, T. Machan, and M. Tang, *Synlett*, 2004, 2670; S. Husinec and V. Savic, *Tetrahedron:Asymmetry*, 2005, **16**, 2047; C. Najera and J. M.



- Sansano, *Angew. Chem. Int. Ed.*, 2005, **44**, 6272; P.-Q. Huang, *Synlett*, 2006, 1133.
8. a) See e.g.: S. W. Goldstein, L. E. Overman, and M. H. Rabinowitz, *J. Org. Chem.*, 1992, **57**, 1179; I. Izquierdo, M. T. Plaza, and J. A. Tamayo, *Tetrahedron:Asymmetry*, 2004, **15**, 3635. b) T. G. Back and K. Nakajima, *J. Org. Chem.*, 2000, **65**, 4543.
  9. M. Turks, X. Huang, and P. Vogel, *Chem. Eur. J.*, 2005, **11**, 465.
  10. B. Deguin, J.-M. Roulet, and P. Vogel, *Tetrahedron Lett.*, 1997, **38**, 6197; J.-M. Roulet, G. Pühr, and P. Vogel, *Tetrahedron Lett.*, 1997, **38**, 6201; V. Narkevitch, K. Schenk, and P. Vogel, *Angew. Chem. Int. Ed.*, 2000, **39**, 1806; V. Narkevitch, S. Megevand, K. Schenk, and P. Vogel, *J. Org. Chem.*, 2001, **66**, 5080; M. Turks, M. C. Murcia, R. Scopelliti, and P. Vogel, *Org. Lett.*, 2004, **6**, 3031; L. C. Bouchez and P. Vogel, *Chem. Eur. J.*, 2005, **11**, 4609; L. C. Bouchez, M. Turks, S. R. Dubbaka, F. Fonquerne, C. Craita, S. LaClef, and P. Vogel, *Tetrahedron*, 2005, **61**, 11473.
  11. M. Turks, F. Fonquerne, and P. Vogel, *Org. Lett.*, 2004, **6**, 1053.
  12. J. A. Dale and H. S. Mosher, *J. Am. Chem. Soc.*, 1973, **95**, 512; D. E. Ward and C. K. Rhee, *Tetrahedron Lett.*, 1991, **32**, 7165.
  13. J. Cossy, C. Willis, V. Bellosta, and S. Samir BouzBouz, *J. Org. Chem.*, 2002, **67**, 1982.
  14. A. M. Salunkhe, P. V. Ramachandran, and H. C. Brown, *Tetrahedron*, 2002, **58**, 10059.